

ABSTRACT

The present invention relates to the human β TrCP protein for the targeting of proteins towards proteasome degradation pathways, which is capable of interacting with the Vpu protein of HIV-1 virus, with the cell proteins I κ B and β -catenin and with the cell protein Skp1p, to its peptide fragments and to the nucleic acid sequences coding for said protein and its fragments.

It further relates to the use of the human β TrCP protein or its peptide fragments for the screening of anti-HIV-1 antiviral agents, antitumoral agents and anti-inflammatory agents, to the antiviral agents, antitumoral agents and anti-inflammatory agents, and to the antibodies directed against said protein and its peptide fragments.